



MEETING AGENDA


Pharmacy and Therapeutics Committee

Virtual Meeting

January 15, 2025 12:00PM – 5:00PM


Registration: <https://events.teams.microsoft.com/event/388d180c-74eb-47d2-bf56-cdedd465302e@eacd16bf-dc0e-44db-8e3f-be370c71feca>

TIME	TOPIC/PRESENTER
12:00 PM	Welcome & Introductions: Suzanne Berman, RPH, AHCCCS Pharmacy Director
12:10 PM	Minutes Review & Vote - P&T October 15, 2024: Suzanne Berman
12:15 PM	<p>Supplemental Rebate Drug Class Review: Clinical review by Umang Patel, PharmD, Magellan/Prime Therapeutics</p> <ol style="list-style-type: none"> 1. Androgenic Agents <ol style="list-style-type: none"> a. Public Testimony: None 2. Antidepressants, Other <ol style="list-style-type: none"> a. Public Testimony: None b. Written Testimony: <ol style="list-style-type: none"> i. Kristina Sabetta 3. Antidepressants, SSRIs <ol style="list-style-type: none"> a. Public Testimony: None 4. Antivirals, Topical <ol style="list-style-type: none"> a. Public Testimony: None 5. Bone Resorption Suppression and Related Agents <ol style="list-style-type: none"> a. Public Testimony: None 6. Bronchodilators, Beta Agonists <ol style="list-style-type: none"> a. Public Testimony: None 7. Colony Stimulating Factors <ol style="list-style-type: none"> a. Public Testimony: None 8. Enzyme Replacement Products, Gaucher Disease <ol style="list-style-type: none"> a. Public Testimony: None 9. Erythropoiesis Stimulating Proteins <ol style="list-style-type: none"> a. Public Testimony: None 10. Hypoglycemics, Alpha Glucosidase Inhibitors



MEETING AGENDA

	<p>a. Public Testimony: None</p> <p>11. Hypoglycemics, Metformins a. Public Testimony: None</p> <p>12. Hypoglycemics, SGLT2s a. Public Testimony: None</p> <p>13. Immunoglobulins a. Public Testimony: None</p> <p>14. Oncology, Oral - Hematologics a. Public Testimony: None</p> <p>15. Ophthalmics, Anti-inflammatory/Immunomodulators a. Public Testimony: None</p> <p>16. Otic Antibiotics a. Public Testimony: None</p> <p>17. Pulmonary Arterial Hypertension Agents a. Public Testimony: None</p> <p>18. Thrombopoiesis Stimulating Agents a. Public Testimony: None</p> <p>19. Ulcerative Colitis a. Public Testimony: None</p>
3:00 PM	<p>New Drug Reviews: Umang Patel</p> <p>1. Yorvipath – palopegteriparatide a. Public Testimony: Michele Rayes</p> <p>2. Hympavzi - marstacimab-hncq</p> <p>3. Livdelzi - seladelpar</p> <p>4. Cobenfy - xanomeline/trospium chloride</p> <p>5. Aqneursa - levacetylleucine</p> <p>6. Miplyffa - arimoclomol</p> <p>7. Ebglyss - lebrikizumab-lbkz</p> <p>8. Voranigo – vorasidenib</p>
3:15 PM	Break & Executive Session: Amber Small, PharmD, Magellan/Prime Therapeutics
4:30 PM	Public Therapeutic Class Votes: Umang Patel/Amber Small



MEETING AGENDA

4:45 PM	Biosimilar Update: Suzi Berman
4:50 PM	Meeting Adjournment 2025 Meeting Dates: May 20 & October 22

DRAFT